Cdk2 and Cdk4 Regulate the Centrosome Cycle and Are Critical Mediators of Centrosome Amplification in p53-Null Cells

Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Molecular and Cellular Biology (Impact Factor: 4.78). 11/2009; 30(3):694-710. DOI: 10.1128/MCB.00253-09
Source: PubMed


The two mitotic centrosomes direct spindle bipolarity to maintain euploidy. Centrosome amplification—the acquisition of ≥3
centrosomes—generates multipolar mitoses, aneuploidy, and chromosome instability to promote cancer biogenesis. While much
evidence suggests that Cdk2 is the major conductor of the centrosome cycle and that it mediates centrosome amplification induced
by various altered tumor suppressors, the role played by Cdk4 in a normal or deregulated centrosome cycle is unknown. Using
a gene knockout approach, we report that Cdk2 and Cdk4 are critical to the centrosome cycle, since centrosome separation and
duplication are premature in Cdk2−/− mouse embryonic fibroblasts (MEFs) and are compromised in Cdk4−/− MEFs. Additionally, ablation of Cdk4 or Cdk2 abrogates centrosome amplification and chromosome instability in p53-null MEFs. Absence of Cdk2 or Cdk4 prevents centrosome amplification by abrogating excessive centriole duplication. Furthermore, hyperactive Cdk2 and Cdk4 deregulate
the licensing of the centrosome duplication cycle in p53-null cells by hyperphosphorylating nucleophosmin (NPM) at Thr199,
as evidenced by observations that ablation of Cdk2, Cdk4, or both Cdk2 and Cdk4 abrogates that excessive phosphorylation. Since a mutant form of NPM lacking the G1 Cdk phosphorylation site (NPMT199A) prevents centrosome amplification to the same extent as ablation of Cdk2 or Cdk4, we conclude that the Cdk2/Cdk4/NPM pathway is a major guardian of centrosome dysfunction and genomic integrity.

Download full-text


Available from: Philipp Kaldis
  • Source
    • "Both of these proteins, when overexpressed, induced CA in mammary epithelial cells previously devoid of CA [5-7]. Emerging evidence suggests that CIN and aneuploidy, including single chromosome losses and polyploidy, can ensue from CA and/or cytokinesis defects [2,8-10]. CA has been detected in pre-malignant lesions, DCIS (ductal carcinoma in situ) and in invasive breast tumors [11-14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Centrosome amplification (CA) amongst particular breast cancer subtypes (Her2+ subtype) is associated with genomic instability and aggressive tumor phenotypes. However, changes in signaling pathways associated with centrosome biology have not been fully explored in subtype specific models. Novel centrosome regulatory genes that are selectively altered in Her2+ breast cancer cells are of interest in discerning why CA is more prevalent in this subtype. To determine centrosome/cell cycle genes that are altered in Her2+ cells that display CA (HCC1954) versus non-tumorigenic cells (MCF10A), we carried out a gene microarray. Expression differences were validated by real-time PCR and Western blotting. After the microarray validation, we pursued a panel of upregulated and downregulated genes based on novelty/relevance to centrosome duplication. Functional experiments measuring CA and BrdU incorporation were completed after genetic manipulation of targets (TTK, SGOL1, MDM2 and SFRP1). Amongst genes that were downregulated in HCC1954 cells, knockdown of MDM2 and SFRP1 in MCF10A cells did not consistently induce CA or impaired BrdU incorporation. Conversely, amongst upregulated genes in HCC1954 cells, knockdown of SGOL1 and TTK decreased CA in breast cancer cells, while BrdU incorporation was only altered by SGOL1 knockdown. We also explored the Kaplan Meier Plot resource and noted that MDM2 and SFRP1 are positively associated with relapse free survival in all breast cancer subtypes, while TTK is negatively correlated with overall survival of Luminal A patients. Based on this functional screen, we conclude that SGOL1 and TTK are important modulators of centrosome function in a breast cancer specific model.
    Full-text · Article · Sep 2014 · Cell Division
  • Source
    • "CDK genes are often constitutively expressed and CDKs are relatively stable, whereas cyclin genes exhibit periodic patterns of expression and are subject to regulated degradation. During the transition between G1- and S-phase, cyclin D1 and CDK4 are the first to be expressed during early G1-phase (28). Cell cycle arrest occurs due to the loss of cyclin expression and CDK activity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study compared the effect of resveratrol on HCT116 and Caco‑2 human colon cancer cells. Annexin V/propidium iodide staining, MTT assay and western blot analysis revealed that resveratrol induced cycle arrest in the two cell lines, which was evidenced by cell cycle analysis and changes in the expression of the cell cycle proteins cyclin‑dependent kinase (CDK) 2, CDK4, cyclin D1, proliferating cell nuclear antigen and P21. Furthermore, resveratrol was found to have a strong apoptosis‑inducing effect, which was evidenced through the high percentage of annexin V positive cells and high protein expression of cleaved‑caspase‑7, cleaved‑caspase‑9 and cleaved‑poly(ADP‑ribose) polymerase in the resveratrol‑treated cancer cells. In conclusion, these results demonstrated that resveratrol had greater growth inhibitory and cell cycle arrest effects on Caco‑2 cells than HCT116 cells, through caspase‑dependent and cyclin‑CDK pathways.
    Full-text · Article · Jul 2014 · Molecular Medicine Reports
  • Source
    • "This selective regulation of a Cdk2 target rather than Cdk2 activation per se is quite novel. Other factors, such as Ras, that induce centrosome reduplication via NPM hyperphosphorylation act by increasing total cyclin-dependent kinase activity (Cdk2 or Cdk4) [8],[33],[44]. Because a fraction of RABL6A localizes to centrosomes and can directly bind to NPM, we initially thought it might reduce NPM phosphorylation by physically blocking Cdk2 accessibility to T199. "
    [Show abstract] [Hide abstract]
    ABSTRACT: RABL6A (RAB-like 6 isoform A) is a novel protein that was originally identified based on its association with the Alternative Reading Frame (ARF) tumor suppressor. ARF acts through multiple p53-dependent and p53-independent pathways to prevent cancer. How RABL6A functions, to what extent it depends on ARF and p53 activity, and its importance in normal cell biology are entirely unknown. We examined the biological consequences of RABL6A silencing in primary mouse embryo fibroblasts (MEFs) that express or lack ARF, p53 or both proteins. We found that RABL6A depletion caused centrosome amplification, aneuploidy and multinucleation in MEFs regardless of ARF and p53 status. The centrosome amplification in RABL6A depleted p53-/- MEFs resulted from centrosome reduplication via Cdk2-mediated hyperphosphorylation of nucleophosmin (NPM) at threonine-199. Thus, RABL6A prevents centrosome amplification through an ARF/p53-independent mechanism that restricts NPM-T199 phosphorylation. These findings demonstrate an essential role for RABL6A in centrosome regulation and maintenance of chromosome stability in non-transformed cells, key processes that ensure genomic integrity and prevent tumorigenesis.
    Full-text · Article · Nov 2013 · PLoS ONE
Show more